A robust humoral immune response is crucial for host defense against many invading pathogens. Recognition of cognate Ags by naive B cells and their subsequent production of Ag-specific Abs is a tightly regulated process that prevents improper Ag recognition and untoward immune responses. The expression of various growth factors, cytokines, chemokines, and their receptors in the B cell microenvironment, such as IL-6, CXCR4, and CXCR5, as well as their ligands CXCL12 and CXCL13 (1) , are essential for the progression of B cells through developmental stages and the eventual generation of pathogenspecific Abs by mature B cells. The humoral immune response matures during successive rounds of B cell stimulation in the specialized structure of the germinal center (GC) 3 within the secondary lymphoid follicles, during which affinity maturation and Ig class-switching occurs in response to cytokine signals provided mainly by Th cells (2) . Despite the well-known role of IL-6 and the hypothesized contribution of other cytokines, such as IL-17 (3) to GC development and Ig production, the mechanisms that regulate the activities of these cytokines are still poorly understood.
Products of the cyclooxygenase (COX) enzymes play important roles in the regulation of immunity. Two different COX isoforms exist and are considered to have differing biological roles. COX-1 is constitutively expressed by most cells, and it is known to be involved in the regulation of platelet function and maintenance of gastric mucosa (4, 5) . The second cyclooxygenase isoform, COX-2, is normally undetectable in most healthy tissues and is induced as a key component of innate immune cell function during the inflammatory phase of the immune response (5-7). Although not as well characterized, the COX enzymes have also recently been recognized for their roles in T cell-mediated immunity. COX-2 was implicated in the regulation of lupus patient T cell apoptosis, thereby regulating lupus pathology (8) , and in early thymocyte proliferation and the later maturation of CD4 ϩ Th cells (9) . COX-1 was traditionally considered to have little involvement in the immune response, but more recently it has been shown to direct thymocyte progression from CD4 Ϫ CD8 Ϫ double-negative to CD4 ϩ CD8 ϩ double-positive cells (9) . It was also integral for the induction of the signaling cascade subsequent to TCR engagement, and COX-1 inhibition prevented the activation of the p38 kinase and downstream transcription factors (10, 11) .
In comparison, studies examining roles for COX-1 or COX-2 in B lymphocyte activation and maturation have produced conflicting results. Early in vitro studies suggested that products of COX might be involved in the regulation of Ab production (12) , and both COX isozymes have been implicated in Ab production in vivo, primarily in models of autoimmune disease. In experimental autoimmune encephalomyelitis, inhibition of COX-2 led to increased anti-myelin oligodendrocyte glycoprotein Ab production (13) , whereas nonspecific COX inhibition during type II collagen-induced arthritis significantly decreased collagen-specific IgG titers (14) . Reports of immunization during COX inhibition are equivocal. One group demonstrated that mice lacking COX-2 failed to exhibit Ig class-switching when immunized with human papilloma virus-like particles (15) , whereas another group demonstrated decreased class-switching during nonspecific COX inhibition in response to OVA injection (16) . Few reports have mentioned COX enzymes in the context of an Ab response to infection. We, and others, have previously reported that mice lacking COX-2 activity develop Ab responses comparable to control animals when infected with the bacterium Borrelia burgdorferi (17, 18) . Although drugs that inhibit or alter COX activity are the most commonly used drugs in the world (19, 20) , a thorough understanding of their effects on immunity is lacking.
To address these issues we utilized a murine model of Lyme disease, caused by infection with the spirochete B. burgdorferi. The multisystemic disease induced by B. burgdorferi infection of both humans and animals is the most common vector-borne disease in both the United States and in Europe (21) . When untreated with antibiotics near the time of infection, 60% of individuals develop a severe arthritis, the intense pain and swelling of which is commonly treated with COX-specific inhibitors or traditional nonsteroidal antiinflammatory drugs (tNSAIDs) (22) . Here we show that murine B cells, in response to B. burgdorferi stimulation in vitro, expressed both COX isozymes, and inhibition of either isozyme affected B cell eicosanoid production. In vivo studies utilizing COX-1-or COX-2-specific inhibitors or COX-specific knockout mice demonstrated that COX-1 activity was required for the generation of a full anti-Borrelia IgG response. Further analysis demonstrated that COX-1 was necessary for the development of GC and the production of normal IL-6 and IL-17 levels in response to infection. Our results demonstrate a critical role for COX-1 in the regulation of GC formation and the generation of humoral immunity upstream of IL-6 and IL-17 production during the response to infection. Additionally, these data suggest that commonly used NSAIDs may affect the ability of the host's immune system to effectively protect against pathogens.
Materials and Methods

Animals
Female C3H/HeJ (C3H) mice, 4 -6 wk of age, were purchased from The Jackson Laboratory. COX-2 heterozygous mice (B6;129S7-Ptgs2 tm1Jed ) were purchased as breeders, also from The Jackson Laboratory, and were backcrossed onto the C3H genetic background for 10 generations. Heterozygous mice were then intercrossed to produce knockout and wild-type littermates. COX-1 knockout mice (B6;129P2-Ptgs1 tm1Unc ) and wild-type controls were purchased from Taconic. Animals were housed in a specific pathogen-free facility and given sterile food and water ad libitum. All studies were conducted in accordance with the guidelines of the Animal Care and Use Committee of the University of Missouri.
B lymphocyte isolation and stimulation
B lymphocytes were isolated from total splenocyte preparations using an autoMACS B cell isolation kit (Miltenyi Biotec) according to the manufacturer's instructions for negative selection. B cells were found to be Ͼ99% CD19 ϩ and Ͻ1% CD3 ϩ or CD14 ϩ as determined by flow cytometry. Purified B cells were cultured in complete DMEM (Invitrogen) supplemented with 1% Nutridoma-SP (Roche Applied Science) with or without stimuli for 8, 24, or 36 h or for 7 days for mRNA, protein, eicosanoid, or Ig measurements, respectively. B cells were stimulated with rat antimouse CD40 (0.5 g/ml; SouthernBiotech), B. burgdorferi spirochetes at a multiplicity of infection of 1, B. burgdorferi total Ag (BbAg, 5 g/ml), arachidonic acid (AA, 10 M; Cayman Chemical), or were untreated. The concentration of B. burgdorferi Ag used has been shown to activate B cells and induce their proliferation and differentiation into plasma cells (23) . B cells were stimulated with AA as a positive control for COX-1 stimulation (24) . For the analysis of F prostanoid (FP) and T prostanoid (TP) receptor expression, B cells were stimulated with a multiplicity of infection of 1 and collected at the indicated time points. For FP antagonism the FP antagonist AL-8810 (Cayman Chemical) was dissolved in 100% ethanol as a stock solution and stored at Ϫ20°C until dilution to the working concentration of 50 M in cell culture medium. B cells were preincubated with vehicle or antagonist 30 min before the addition of stimulus, and supernatants were harvested 7 days later. Cell viability was determined by trypan blue staining.
Inhibition of COX-1 or COX-2
Celecoxib (LKT Laboratories) and SC-560 (Cayman Chemical) were dissolved in 100% ethanol/0.01% Tween 20 or 100% ethanol alone, respectively, as stock solutions and stored at Ϫ20°C until dilution to the working concentration of 1 M in cell culture medium. Treatment of cells with COX inhibitor concentrations Ͼ10 M increased cell death in dose-response studies. B cells were preincubated with inhibitors or vehicle for 30 min before the addition of stimuli. For in vivo inhibition of COX-2, celecoxib was incorporated into a normal laboratory diet (Research Diets) as described (25) . Animals were fed celecoxib chow beginning day Ϫ1 of infection with B. burgdorferi, and control animals were fed normal rodent chow (Purina PicoLab 5053; Purina Mills). For in vivo COX-1 inhibition, dilutions of SC-560 were mixed daily in 200 l of sterile PBS and animals were treated once daily by oral gavage for a final dosage of 10 mg/kg/day.
RNA and RT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer's protocol. One-step RT-PCR was performed using the EZ RT-PCR kit (Applied Biosystems) and 100 ng of total RNA with the ABI Prism 7700 sequence detection system (Applied Biosystems). The mouse Nidogen gene, a single copy gene, was used as an endogenous control as described previously (26) . COX-1 and COX-2 primer sequences were described previously (17) . RT-PCR conditions were: 50°C for 15 min, 60°C for 30 min, 95°C for 10 min, and 45 cycles of 95°C for 30 s and 60°C for 1 min.
SDS-PAGE/Western analysis
Total protein was isolated in 40 l of modified radioimmunoprecipitation assay buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM PMSF, 1 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS). Thirty micrograms was fractionated on a 10% SDS-PAGE gel and transferred electrophoretically to polyvinylidene difluoride membrane (Millipore). Membranes were incubated with a 1/1000 dilution of rabbit antimouse COX-1, COX-2, PGF 2␣ receptor (FP), or thromboxane (TX)B 2 receptor (TP) (Cayman Chemical) or GAPDH (Bethyl Laboratories) primary Ab. Protein detection was performed using the Vectastain ABC-AmP kit (Vector Laboratories) according to the manufacturer's instructions.
Flow cytometric detection of COX-2
Following stimulation, B lymphocytes were collected and washed with 5% FBS in PBS (FBS-PBS) and stained at a density of 1 ϫ 10 6 cells/100 l. Surface staining was performed with fluorescein (FITC)-conjugated rat antimouse CD19 Ab (eBioscience) in 5% FBS-PBS for 15 min at room temperature. Intracellular staining was performed for COX-2 protein using a PE-labeled mouse anti-human IgG1 Ab that displays cross-reactivity with mouse COX-2 or the isotype control (Santa Cruz Biotechnology) and a Fix-Perm kit (Caltag Laboratories) according to the manufacturer's instructions. Flow cytometric data were collected on a FACScan flow cytometer and analyzed using CellQuest software (BD Biosciences).
Bacteria and infections
A virulent, low-passage, clonal isolate of the B. burgdorferi N40 strain (a gift from J. Weis, University of Utah) was used for all infections. Frozen stocks were placed in 7.5 ml of Barbour-Stoenner-Kelly (BSK) II medium (Sigma-Aldrich) with 6% rabbit serum (Sigma-Aldrich) and grown to log phase by incubation for 5-6 days at 32°C. Spirochetes were enumerated using dark field microscopy and a Petroff-Hausser counting chamber (Hausser Scientific). Spirochete dilutions were made in sterile BSK II medium and mice were inoculated in both hind footpads with 2.5 ϫ 10 5 B. burgdorferi organisms in 50 l of medium, a concentration that reliably produces arthritis in susceptible animals and is a typical inoculum (17, 27) .
Determination of Ab levels
B. burgdorferi-specific IgM and IgG levels in the sera of infected animals were determined by ELISA using alkaline phosphatase-conjugated antimouse IgM and IgG as a modification of Bolz et al. (28) . Immulon 2B ELISA plates (Nalgene) were coated with 0.5 g/ml B. burgdorferi Ag in coating buffer (0.1 M bicarbonate buffer (pH 9.4)). Two columns on each plate were reserved for the standard curve. These wells were coated with rat anti-mouse IgG (20 g/ml; AnaSpec) or goat anti-mouse IgM (20 g/ ml; SouthernBiotech) in coating buffer. For total nonspecific Ig from sera or cell culture supernatant, the plate was coated with rat anti-mouse IgG or goat anti-mouse IgM. Standard curves were created by 1/3 dilution of purified mouse total IgG (Equitech-Bio) or IgM (Bethyl Laboratories). Cell culture supernatants or sera of individual animals were diluted in BSA/PBS and incubated for 2 h at room temperature. Alkaline phosphatase-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories) or rat anti-mouse IgM (SouthernBiotech) was applied at 1/1000 dilution. Plates were washed and read at 409 nm after addition of the phosphatase substrate (Sigma 104 tablets; Sigma-Aldrich).
Measurement of eicosanoids from cell culture
B lymphocyte culture supernatants were analyzed by enzyme immunoassay (Cayman Chemical) for the presence of PGE 2 , PGF 2␣ , and TXB 2 (as a measure of TXA 2 ) after 36 h of incubation in the presence of stimulus and/or inhibitor(s).
Measurement of eicosanoids from spleen tissue
Tissues were snap-frozen in liquid nitrogen and stored at Ϫ80°until extraction. Spleens were pulverized and the resulting powder was placed in 3 ml of 50% ethanol in water and then weighed. Ten microliters of antioxidant cocktail (0.2 mg/ml butylated hydroxytoluene, 0.2 mg/ml EDTA, 2 mg/ml triphenylphosphine, 2 mg/ml indomethacin in a solution of 2/1/1 methanol-ethanol-H 2 O) was added to each sample before incubation at Ϫ20°C for 72 h. Samples were then centrifuged at 3500 ϫ g for 30 min, and the clear ethanolic supernatant was removed to a new tube and dried under nitrogen gas. Samples were reconstituted with 2 ml of 10% methanol and supplemented with 50 l of 50 pg/l (2.5 ng total) of deuterated internal standards, all from Cayman Chemical. Samples were sonicated for 30 s, purified by solid phase extraction as previously described (29), and stored at Ϫ20°C until analysis. Samples were evaporated and then reconstituted in 50 l of liquid chromatography (LC) solvent A (water-acetonitrile-acetic acid (70:30:0.02; v/v/v)) immediately before analysis. The analysis of eicosanoids was performed by LC-tandem mass spectrophotometry (MS/MS), based on previously published methodology (29) . Eicosanoids were separated by reverse-phase LC on a Synergy C18 column (2.1 ϫ 250 mm, 4 microns; Phenomenex) at a flow rate of 300 l/min at 50°C. The column was equilibrated in solvent A (water-acetonitrile-acetic acid (70:30:0.02; v/v/v)), and 40 l of sample was injected using a 50-l injection loop and eluted with 0% solvent B (acetonitrile-isopropyl alcohol (50:50; v/v)) between 0 and 1 min. Solvent B was increased in a linear gradient to 25% solvent B until 3 min, to 45% until 11 min, to 60% until 13 min, to 75% until 18 min, and to 90% until 18.5 min. Solvent B was held at 90% until min 20, dropped to 0% by 21 min, and held until 25 min.
Eicosanoids were analyzed using a tandem quadrupole mass spectrometer (ABI 4000 Q Trap; Applied Biosystems) via multiple-reaction monitoring in negative-ion mode. The electrospray voltage was Ϫ4.5 kV and the turbo ion spray source temperature was 525°C. Collisional activation of eicosanoid precursor ions used nitrogen as a collision gas. Eicosanoids were measured using the following precursor3product multiple reaction monitoring pairs: (d 4 -PGJ 2 (3153271). Quantitative eicosanoid determination was performed by the stable isotope dilution method (30) . A standard curve was prepared by adding 2.5 ng of each internal (deuterated) eicosanoid standard to the following amounts of eicosanoid (nondeuterated) primary standard: 0.1, 0.3, 1, 3, 10, 30, and 100 ng.
Measurement of serum cytokines
Serum concentrations of IL-6 and IL-17 were determined by ELISA according to the manufacturer's instructions (eBioscience).
Quantification of GCs in the spleen
Each spleen was cut into four serial sections 100 m apart. Composite overview images of each spleen were produced using multiple image alignment in the Olympus MicroSuite FIVE software (Olympus America), and Adobe Photoshop software (Adobe Systems) was used to equalize brightness and contrast across aligned panels. Total spleen area and Ki67 ϩ area were measured using the same software. Spleen area was determined by averaging the measurements of all four sections. Average GC areas were determined across all four sections of each individual spleen. Images were acquired with an Olympus DP71 camera attached to an Olympus BX40 light microscope using the MicroSuite FIVE software.
Quantification of GC B cells
Flow cytometry was used to determine the percentage of GC B cells in the spleens of wild-type or COX-1°mice 10 days following infection with B. burgdorferi. Single-cell suspensions of splenocytes were made and red cells removed by hypotonic lysis. B cells were stained with PE-B220 and AF647-GL7 (eBioscience). Percentages of stained cells were determined in a live gate and using CellQuest software (BD Biosciences).
Administration of IL-6 and IL-17
Recombinant mouse IL-6 (rmIL-6; Biomyx) and IL-17 (rmIL-17; R&D Systems) were reconstituted in sterile Dulbecco's PBS (Invitrogen) and administered s.c. at doses of 4 g/mouse/day or 0.5 g/mouse/day, respectively, in a total volume of 100 l of PBS (31, 32) . Vehicle-treated controls received 100 l of PBS alone. Animals were treated beginning day 0 of infection and once daily thereafter though day 7 of infection.
Borreliacidal Ab assay
The determination of borreliacidal activity was performed as described previously with some modifications (33, 34) . Sera from B. burgdorferiinfected mice were diluted 1/5 in PBS, heat-inactivated at 55°C for 1 h, and filter-sterilized through a 0.22-m pore-size filter. Spirochetes were grown to log phase at 32°C and then diluted to a final concentration of 1 ϫ 10 8 /ml in BSK media. One hundred microliters of diluted B. burgdorferi was added to wells of a 96-well round-bottom microtiter plate. Ten microliters of filter-sterilized guinea pig serum (active complement; Innovative Research) was added to each well and then 100 l of serum from individual animals was added. Sera from naive mice were used as controls. Wells containing only B. burgdorferi were used to determine basal levels of dead bacteria. The plate was gently mixed and incubated at 32°C for 16 h. Assays were performed in duplicate. After incubation, the wells were washed with serum-free BSK and bacterial viability was determined using the Live/Dead BacLight bacterial cell viability kit according to the manufacturer's instructions (Invitrogen). At least 100 spirochetes total were counted as either live or dead, and the final percentage of killed Borrelia was determined by subtracting the basal percentage of dead bacteria present in the untreated control Borrelia wells. Values are presented as the percentage of borreliacidal activity of sera from different treatment groups as compared with the vehicle-treated control.
Statistical analysis
Data were analyzed by one-way ANOVA, Student's t test, or Mann-Whitney rank sum test using the SigmaStat 3.5 software (Systat Software). Differences with p values Յ0.05 were considered significant. Error bars represent Ϯ SD.
Results
Murine B cells constitutively express COX-1 and up-regulate both COX-1 and COX-2 in response to stimulation with B. burgdorferi
Most cell types express COX-1 constitutively and many can induce COX-2 expression upon stimulation (5, 7); however, their expression in normal murine B cells has not been demonstrated. Splenic B cells were isolated from C3H/HeJ mice and exposed to various stimuli for 8 h in vitro to determine whether murine B cells expressed COX-1 or COX-2 mRNA or protein in response to stimulation. Fig. 1A shows low levels of constitutive COX-1 and COX-2 mRNA expression in naive B cells that were increased upon activation with B. burgdorferi or anti-CD40 stimulation. Anti-CD40 is a nonspecific activator of B cells, and B. burgdorferi has been shown to have B cell mitogenic effects (23, 35) .
Although traditionally considered to be constitutively expressed, posttranscriptional regulation of COX-1 protein expression has been shown in some disease conditions (36) . Conversely, COX-2 transcription and translation are both positively and negatively regulated by numerous signals, with most regulation occurring posttranscriptionally (6) . Western blot analysis (Fig. 1B) demonstrated constitutive expression of COX-1 protein in unstimulated murine B cells, and this expression was greatly increased upon stimulation with B. burgdorferi. In contrast, stimulation of B cells with anti-CD40 had only a minor effect on the expression levels of COX-1 protein. COX-2 protein levels were undetectable in unstimulated or anti-CD40-stimulated B cells; however, in response to B. burgdorferi stimulation COX-2 protein levels were also greatly increased (Fig. 1C ). To specifically demonstrate that the B cells and not some other contaminating cell 
Stimulation of murine B cells induces the production of prostaglandins and expression of their receptors
We subsequently assayed the ability of murine B cells to produce representative COX-1 and COX-2 products, PGE 2 , PGF 2␣ , and TXB 2 , in vitro in response to coculture with B. burgdorferi. Unstimulated B cells produced low levels of PGF 2␣ , TXB 2 , and PGE 2 ( Fig. 2A) . Exogenous AA was used as a positive control for COXmediated eicosanoid production and thus represents the capacity of the cell cultures to produce eicosanoids. Incubation of naive B cells with live B. burgdorferi induced production of PGF 2␣ , TXB 2 , and low levels of PGE 2 . Anti-CD40 stimulation induced small but significant ( p Ͻ 0.01) increases in PGF 2␣ and TXB 2 production, but it had no effect on the production of PGE 2 . Previous studies have shown that murine B cells respond to PGE 2 in vitro via the PGE 2 receptors EP 2 and EP 4 (37) . To address the possibility that PGF 2␣ and TXB 2 may also act in an autocrine manner, Borreliastimulated B cells were assayed for expression of the PGF 2␣ receptor FP, and the TXB 2 receptor TP. No basal production of FP or TP proteins was detected; however, protein for both receptors was up-regulated after just 30 min of incubation with B. burgdorferi (Fig. 2B) . Whereas FP expression remained high throughout the time course, TP protein expression appeared to peak at ϳ6 -12 h poststimulation and had returned to baseline levels by 72 h. These data imply that murine B cells may be subject to autocrine regulation by these eicosanoids, perhaps with different kinetics, within the B cell microenvironment.
Murine B cells produce prostaglandins via both COX-1 and COX-2
This eicosanoid profile generated in vitro implicated both COX-1 and COX-2 involvement in B cell responses to live B. burgdorferi. We therefore examined the response of purified murine B cells to various stimuli in the presence or absence of the COX-1-specific inhibitor SC-560 (38), the COX-2-specific inhibitor celecoxib (CLX), or both inhibitors in combination (SCX) (Fig. 3) . AA was added as the positive control and represents the maximum capability of the cells to produce each eicosanoid under the given conditions. The lack of an effect by CLX on the AA-stimulated cells likely reflects the low levels of COX-2 present in naive B cells without additional stimuli. Anti-CD40-stimulated B cells produced very little PGE 2 or TXB 2 , but they were capable of producing burgdorferi stimulation, naive B cells were capable of making high levels of all three eicosanoids tested, and the production of each could be reduced by blocking either COX pathway. These results demonstrate that both COX-1 and COX-2 are active in stimulated B cells and are capable of producing inflammatory eicosanoids.
Mice deficient in COX-1 activity produce less pathogen-specific IgG
Our in vitro data indicated that both COX-1 and COX-2 could produce prostaglandins in response to B cell stimulation. Addition of PGE 2 to in vitro cultures of B cells has been reported to increase Ab production (39) , while in vitro inhibition of human B cell COX-2 activity can decrease both IgM and IgG production (40) . However, the specific contribution of COX-1 to Ab production has not been described. To determine the relative in vivo contribution of the two COX isoforms to the overall composition of the humoral response during a primary infection, we examined the effect of COX-1-and COX-2-specific inhibition on the ability of C3H mice to mount a humoral response to B. burgdorferi infection. C3H/HeJ mice were infected with B. burgdorferi and treated daily with either a COX-2 inhibitor, COX-1 inhibitor, or both in combination. Sera were collected at time points that correlated to the peak (day 14) and the resolution phases (day 24) of disease and were assayed for B. burgdorferi-specific IgM and B. burgdorferispecific-total IgG levels. At day 14 of infection, only the dual inhibition of both COX-1 and COX-2 had a significant effect ( p Յ 0.05) on decreasing IgM production (Fig. 4A) , an effect that was abrogated by day 24 postinfection. Total Borrelia-specific IgG levels were similarly decreased by dual inhibition of COX-1 and COX-2 at day 14 postinfection. Total IgG subset levels were also minimally affected by either enzyme alone. Dual inhibition significantly decreased IgG2b levels at days 14 and 24 and IgG3 levels at day 24 (data not shown). Thus, inhibition of COX-1 or COX-2 did not appear to cause a global Th1/Th2 skewing of the immune response. In contrast to IgM, however, Borrelia-specific IgG levels were significantly decreased by inhibition of COX-1 alone at day 24 of infection ( p Յ 0.05), while inhibition of COX-2 activity had no effect. Thus, pathogen-specific IgG production was susceptible to in vivo inhibition of COX-1 alone or both isozymes in concert, but not COX-2 alone. These data suggested that COX-1 predominated over COX-2 in the regulation of Ab production in vivo.
To further define the role of either isozyme in vivo, we infected COX-1°or COX-2°mice with B. burgdorferi and measured Borrelia-specific Abs at days 14 and 24 postinfection. Levels of total IgG at day 0 were not different between wild-type and COX-1°or COX-2°mice (Fig. 4, B and C) , and B. burgdorferi-specific IgG levels were undetectable at this time point. Constitutive (day 0) IgM levels in COX-2°mice were comparable to their wild-type littermates (Fig. 4B ), as were the B. burgdorferi-specific IgM and total IgG responses at days 14 and 24 postinfection. Similar results were seen in COX-2-deficient mice on a DBA/2J background (data not shown), which is a mouse strain resistant to the development of Lyme arthritis. These findings demonstrate that a pathogenspecific Ig response can be mounted in the context of a complete lack of COX-2 activity, which suggests that COX-1 function must predominate in regulating the humoral response to infection.
To confirm the role of COX-1 in the generation of humoral immunity, we examined the ability of COX-1°mice to develop a B. burgdorferi-specific humoral response (Fig. 4C) . COX-1°mice demonstrated significantly higher basal levels of IgM, as well as significantly higher Borrelia-specific IgM levels, at both day 14 and day 24 postinfection. Although Borrelia-specific total IgG was not different between knockout and wild-type animals at day 14 postinfection, Borrelia-specific IgG was significantly lower at day 24 postinfection in the COX-1°mice ( p Ͻ 0.05). Thus, COX-1 deficiency resulted in increased Borrelia-specific IgM levels and decreased Borrelia-specific IgG production following infection with B. burgdorferi. These data are consistent with a regulatory mechanism for pathogen-specific Ab production that is dependent on COX-1 activity and is thus susceptible to its inhibition.
COX-1-deficient mice have defective GC formation
GC formation is central to the development of a pathogen-specific humoral immune response. For instance, animals lacking Bcl-6 or CXCR5 demonstrated lower or absent Ag-specific Ab production correlative with altered splenic architecture and decreased GC size or number (41, 42) . Since pathogen-specific IgG levels were most affected by a lack of COX-1 activity, we hypothesized that COX-1 was affecting the development of humoral immunity by altering the development of GC. Spleens from COX-1°and wild-type control animals were evaluated for development of GCs 10 days after B. burgdorferi infection. Ki67 staining for proliferating cells (43) demonstrated few GCs in the spleens of uninfected (day 0) WT or COX-1°mice (Fig. 5A) . However, by day 10 postinfection abnormalities were apparent in the distribution of proliferating cells in the spleens of COX-1-deficient mice compared with controls. Composite photographs of representative H&E-stained spleens from WT and COX-1° (Fig. 5B) mice illustrated the altered splenic architecture in COX-1°animals, particularly the lack of well-defined light and dark zones. Although the number of GCs per splenic section was not altered and the difference in spleen area only inclined toward an increase in size in COX-1°mice, morphometric analyses demonstrated a significant decrease in the size of COX-1°GC ( p ϭ 0.014) and, consequently, the percentage of the total splenic area that was occupied by GCs ( p ϭ 0.005) as shown in Fig. 5C . Flow cytometry was used to determine the number of GC B cells (Fig. 5, D and E) . Spleens from COX-1°mice had a decrease of ϳ36% in GC B cells at 10 days postinfection. These data suggested that COX-1 was governing the production of a key regulator or regulators of the GC development process and ultimately the production of pathogen-specific IgG molecules.
Mice deficient in COX-1 activity produce decreased levels of prostaglandins and cytokines
Our in vitro data indicated that murine B cells were capable of producing several prostaglandins that could play a role in Ab responses. While PGE 2 is most commonly linked with lymphocyte responses, the involvement of other eicosanoids has not been investigated. We therefore took a lipidomics approach to quantify changes in eicosanoid profiles in the spleens of wild-type and COX-1°mice following infection with B. burgdorferi. Spleens from B. burgdorferi-infected COX-1°mice were removed at 10 days postinfection and levels of eicosanoids were quantified by LC-MS/MS (29) . Levels of prostanoids (PGs and TX) in spleens from wild-type and COX-1°mice are shown in Table I . Levels of other eicosanoids were mostly unchanged and are not shown. We found significant ( p Յ 0.01) decreases in several prostaglandins in spleens of COX-1°vs wild-type mice. These include 6-keto PGF 1␣ (a stable derivative of PGI 2 ), TXB 2 , PGF 2␣ , and PGJ 2 , while levels of PGE 2 and PGD 2 were reduced by 50% compared with wild-type mice, but were not statistically significant. Levels of other prostaglandins were unchanged. These data suggest that prostaglandins other than PGE 2 may also have a role in B cell activation and in regulating Ab responses. To investigate this possibility we isolated B cells from uninfected mice and treated them with SC-560 or AL-8810 (an FP antagonist) 30 min before their in vitro stimulation with B. burgdorferi. Treatment of B cells with either SC-560 or AL-8810 resulted in a significant decrease ( p Ͻ 0.05) in B cell activation as measured by IgM and IgG production (Fig. 6) . These results suggest that B cell COX-1 production of PGF 2␣ may play an important role in regulating B cell activation.
IL-6 is necessary for GC development and therefore Ab production (2), and IL-6 production by some cell types is regulated by PGF 2␣ and TXB 2 (44, 45) . We therefore hypothesized that COX-1 was affecting the humoral immune response via the regulation of IL-6 production. We assayed levels of IL-6 in the serum of B. burgdorferi-infected mice at 24 days postinfection treated with a COX-1 or COX-2 inhibitor and found that serum IL-6 levels were significantly decreased only in animals treated with the COX-1 inhibitor ( p ϭ 0.004; Fig. 7A ). IL-6 was also significantly decreased at 24 days postinfection in mice deficient in COX-1 ( p Ͻ 0.05; Fig. 7B ). Additionally, sera from COX-1 inhibitor-treated mice at day 24 postinfection were assayed for the production of IL-17, which has been shown to regulate IL-6 production (46) and, more recently, has been proposed as a regulator of the immune response in autoantibody-mediated disease (3) . Serum levels of IL-17 were also significantly decreased in COX-1 inhibitor-treated animals as compared with vehicle-treated controls ( p ϭ 0.03; Fig.  7C ). These data suggest that products of COX-1 regulate the development of humoral immunity by operating upstream of IL-6 and IL-17 production.
Addition of IL-17 to COX-1-inhibited mice restores pathogen-specific IgG production
To address whether the decrease in pathogen-specific IgG production in mice lacking COX-1 activity was a direct result of decreased IL-6 and/or IL-17 production, we first determined if administration of exogenous IL-6 would restore to control levels the production of B. burgdorferi-specific IgG in COX-1 inhibitortreated animals. Mice were infected with B. burgdorferi, treated daily with vehicle or SC-560, and rmIL-6 was administered once daily on days 1-7 postinfection and B. burgdorferi-specific Abs were measured at day 24 postinfection. Administration of rmIL-6 resulted only in a partial restoration of B. burgdorferi-specific IgG levels ( p ϭ 0.2 vs vehicle-treated animals; p ϭ 0.1 vs SC-560-treated animals; Fig. 8A ), which led us to examine whether delivery of IL-17, either alone or in combination with IL-6, would fully restore pathogen-specific Ab production in COX-1 inhibitortreated mice. Animals infected with B. burgdorferi were treated with vehicle or COX-1 inhibitor and were administered rmIL-17 alone or rmIL-17 and rmIL-6 on days 1-7 postinfection (Fig. 8B) . By day 24 of infection, exogenous IL-17 alone fully restored B. burgdorferi-specific IgG production in mice treated with SC-560. Thus, products of COX-1 appear to be required for the generation of pathogen-specific IgG via regulation of IL-17 production.
Ab-mediated killing of spirochetes is decreased during COX-1 inhibition and is restored upon treatment with IL-17
Although pathogen-specific IgG Ab levels were significantly decreased in the absence of COX-1 activity, we wanted to ascertain whether this correlated to a functional defect in humoral immunity. Borreliacidal Ab levels correlate with the resolution of disease and provide protection against challenge with the Lyme disease pathogen (33, 34) . To provide additional evidence for the necessity of COX-1 to the humoral immune response, we assayed the borreliacidal activity of serum at day 14 postinfection from B. burgdorferi-infected mice treated with vehicle, COX-1 inhibitor, or COX-1 inhibitor plus exogenous IL-17 (Fig. 8C) . Borreliacidal activity of sera from vehicle-treated animals was set at 100% killing activity. Sera from COX-1 inhibitor-treated animals was Ͻ50% as effective in killing Borrelia spirochetes as vehicletreated sera. Administration of rmIL-17 during COX-1 inhibition restored borreliacidal activity of the sera, consistent with the increase in anti-Borrelia Ab production. Thus, the decrease in antiBorrelia Abs affected by COX-1 inhibition resulted in a dramatic decrease in bacterial killing, further confirming the functional importance of COX-1 regulation of humoral immunity.
Discussion
Products of the COX enzymes, particularly PGE 2 , significantly affect immune cell function and participate in the pathogenesis of several autoimmune diseases (36, (47) (48) (49) (50) . The discovery of COX-2, which is induced by inflammatory stimuli, led to the idea that the constitutive isoform, COX-1, had little to no involvement in regulating the immune response (7, 38) . However, recent studies suggest that COX-1 may be actively involved in immunoregulation (36) . In this report, we demonstrate that COX-1 products fulfill an unsuspected critical role in the humoral immune response by promoting isotype-switching and the efficient development of pathogen-specific IgG via IL-17 production.
Increasing evidence indicates that IL-17 plays a significant role in Ab production. IL-17°mice developed lower levels of anti-TNP Abs in a model of contact hypersensitivity (51) , and GC development and isotype-switching were impaired in a model of autoimmune arthritis (3) . Studies investigating the role of PGE 2 in the regulation of immunity with regard to IL-17 have been conducted primarily in vitro and have utilized exogenous PGE 2 . Incubation of naive human or mouse T cells with PGE 2 concomitant with activation led to an increased number of cells differentiated to the Th17 phenotype with enhanced IL-17 production per cell (52, 53) . Because PGE 2 production is responsive to IL-17, and vice versa, it is tempting to conclude that as the "proinflammatory" COX isoform, COX-2 is necessary for governing this response. However, experiments in which PGE 2 production was inhibited in the context of T cell IL-17 production have utilized indomethacin, a nonspecific inhibitor of COX activity, leaving open the question of which COX isoform was in fact responsible for modulating IL-17 production.
To date, no studies have examined the differential activity of COX-1 and COX-2 in B cells. Our data demonstrated that normal murine B cells express both COX-1 and COX-2 and are capable of producing PGE 2 , as well as PGF 2␣ and TXB 2 via either enzyme. B cells have the capacity to respond to these eicosanoids in an autocrine manner, since both FP and TP were expressed upon stimulation. These data build on earlier work, where PGF 2␣ was demonstrated to affect DNA synthesis and excision repair in murine splenocytes (54) , implying that this lipid may be essential for Ig isotype-switching. Blockade of FP resulted in a significant decrease in IgM and IgG in vitro, equivalent to the suppression seen using the COX-1-specific inhibitor SC-560, demonstrating that products of COX-1 other than PGE 2 , such as PGF 2␣ and TXB 2 , may influence the immune response by a number of pathways, one of which could be autocrine regulation of Ig production. Although we have demonstrated that murine B cells produce PGF 2␣ and TXB 2 in vitro, further studies are needed to determine which cells of the splenic microenvironment produce these eicosanoids in vivo and whether other cells of the GC, such as follicular dendritic cells or T cells, are regulated by these same eicosanoids in an autocrine manner, subsequently regulating IL-6 and IL-17 production.
Neither COX-1 nor COX-2 has been linked to GC formation; however, COX-2 has been mentioned tangentially as a contributor to humoral immunity, with the assumption that the effect was mediated via alteration of the Th1-Th2 axis (29) . Our data demonstrate that animals deficient in COX-1 demonstrated abnormal splenic architecture and failed to develop normal GC following infection with B. burgdorferi. Additionally, although COX-1 activity was necessary for the production of normal serum IL-6 and IL-17 levels, the addition of exogenous IL-17 alone fully restored pathogen-specific IgG production and borreliacidal activity in mice treated with a COX-1-specific inhibitor, supporting the hypothesis that IL-17 functions in the normal humoral immune response to infection. Furthermore, although previous studies have demonstrated that IL-17 can increase COX-2 mRNA production and, conversely, that the COX product PGE 2 can increase IL-17 production, this is the first study to identify COX-1 as the isozyme that influences IL-17 in vivo. Additionally, although studies have focused on the contribution of PGE 2 as the master eicosanoid involved in modulation of the acquired immune response, lipidomic analyses revealed copious production of several other COX products in the spleen, chiefly PGF 2a and TXB 2 , illustrating the unexplored potential for other in vivo lipid mediators of IL-17-mediated Ab production.
Since dual inhibition in vivo had the earliest effect on pathogenspecific IgG production, this implies that compensation may be a factor when inhibition of only one COX isozyme is employed. This also indicates that drugs that inhibit both isozymes equally (tNSAIDs) may have a greater clinical effect with regard to Ab production by blocking compensatory activity of COX-2 during COX-1 inhibition. The use of COX-1°mice clearly illustrated the pivotal role of the COX-1 isozyme in the development of pathogen-specific Ab responses, as these animals demonstrated increased IgM and decreased B. burgdorferi-specific IgG, indicative of a class-switching defect.
Both IL-6 and IL-17 are mediators of the adaptive immune response to Borrelia infection. IL-6°mice infected with B. burgdorferi, Listeria monocytogenes, or vesicular stomatitis virus, among others, have significantly lowered serum levels of Ag-specific IgG (55, 56) . More recently the contribution of IL-17 as a modulator of the humoral immune response has been explored in models of autoimmunity. Decreased levels of IL-17 correlated with decreased autoantibody production in several animal models of autoimmune disease (57, 58) , which has subsequently been linked to the regulation of GC generation (3) . Although these previous studies indicated a role for IL-17 in the genesis of autoantibodies, the present study is the first to demonstrate that IL-17 plays a role in the generation of Abs during the normal humoral immune response to infection. The connection between COX-1, IL-17, and humoral immunity was confirmed in the borreliacidal activity assay. The ability of Abs to kill Borrelia is commonly used as a diagnostic tool to determine the efficacy of clinical treatments for Lyme disease (34, 59) . We therefore utilized this assay to demonstrate that the decreased Ab levels induced by COX-1 inhibition lead to a clear functional decrease in the ability of Abs to kill Borrelia spirochetes. This defect was recovered in animals treated with exogenous IL-17, restoring borrreliacidal activity in animals treated with COX-1 inhibitors and establishing a clear role for COX-1 activity in the generation of a functional humoral immune response.
The use of the B. burgdorferi infection model demonstrates that in response to a clinically relevant pathogen, products of COX-1 govern the humoral response via regulation of IL-6 and IL-17 production, and the generation of GC. The description of this previously unappreciated role for COX-1 not only expands our understanding of the regulation of humoral immunity, but comes at a time when the use of alternatives to COX-2-specific inhibitors is on the rise (60) in addition to the already prevalent use of tNSAIDs (19, 20) . Although it is predicted that patients using COX-1-specific inhibitors or tNSAIDs may be more susceptible to infectious agents or have decreased responses to vaccine preparations, this study also reveals COX-1 as a potential therapeutic target in conditions caused by pathologic Ab production.
